Burning mouth syndrome

Dermatologic Therapy

Volumn 23, Issue 3, 2010, Pages 291-298

  Torgerson, Rochelle R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Burning mouth syndrome; Evaluation; Pathophysiology; Treatment

Indexed keywords

AMITRIPTYLINE; BENZYDAMINE; BETHANECHOL; BIOTENE; CAPSAICIN; CHLORDIAZEPOXIDE; CLONAZEPAM; DOXEPIN; GABAPENTIN; LACTOPEROXIDASE; LIDOCAINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; PREGABALIN; SERTRALINE; THIOCTIC ACID; TRAZODONE; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANESTHETIC AGENT;

ATROPHY; BEDTIME DOSAGE; BEHAVIOR THERAPY; BURNING MOUTH SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COPING BEHAVIOR; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DYSGEUSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; JOB SATISFACTION; LABORATORY TEST; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; ORAL BIOPSY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL EXAMINATION; PHYSICIAN; PREVALENCE; PSYCHOSOMATIC DISORDER; QUALITY OF LIFE; REVIEW; SALIVARY GLAND DISEASE; TASTE DISORDER; XEROSTOMIA; AGED; COMPLICATION; FEMALE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PERIPHERAL NERVOUS SYSTEM DISEASES; POSTMENOPAUSE; SEX DIFFERENCE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; ANESTHETICS; BURNING MOUTH SYNDROME; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; POSTMENOPAUSE; SEX FACTORS;

EID: 77952713230     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01325.x     Document Type: Review

References (69)

1. Haberland, CM, Allen CM, Beck FM. Referral patterns, lesion prevalence, and patient care parameters in a clinical oral pathology practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 : 87 : 583 588.
2. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 1993 : 124 : 115 121.
3. Grushka M, Sessle BJ. Burning mouth syndrome. Dent Clin North Am 1991 : 35 : 171 184.
4. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed) 1988 : 296 : 1243 1246.
5. Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987 : 63 : 30 36. (Pubitemid 17010208)
6. Gorsky M, Silverman S Jr., Chinn H. Burning mouth syndrome: a review of 98 cases. J Oral Med 1987 : 42 : 7 9.
7. Albuquerque RJ, de Leeuw R, Carlson C, Okeson J, Miller C, Andersen A. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: an fMRI study. Pain 2006 : 122 : 223 234.
8. Jaaskelainen SK, Rinne JO, Forssell H, et al. Role of the dopaminergic system in chronic pain - a fluorodopa-PET study. Pain 2001 : 90 : 257 260.
9. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003 : 101 : 149 154.
10. Jaaskelainen SK, Forssell H, Tenovuo O. Abnormalities of the blink reflex in burning mouth syndrome. Pain 1997 : 73 : 455 460.
11. Forssell H, Jaaskelainen SK, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain 2002 : 99 : 41 47.
12. Clifford TJ, Warsi MJ, Burnett CA, Larney PJ. Burning mouth in Parkinson's disease sufferers. Gerodontology 1998 : 15 : 73 78.
13. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003 : 110 : 1215 1224.
14. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 1998 : 844 : 153 165.
15. Grushka M, Sessle BJ, Howley TP. Psychophysical assessment of tactile, pain and thermal sensory functions in burning mouth syndrome. Pain 1987 : 28 : 169 184.
16. Ito M, Kurita K, Ito T, Arao M. Pain threshold and pain recovery after experimental stimulation in patients with burning mouth syndrome. Psychiatry Clin Neurosci 2002 : 56 : 161 168.
17. Lauria G, Majorana A, Borgna M, et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 2005 : 115 : 332 337.
18. Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007 : 14 : 864 871.
19. Lundy FT, Al-Hashimi I, Rees TD, Lamey PJ. Evaluation of major parotid glycoproteins in patients with burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 : 83 : 252 258.
20. Tammiala-Salonen T, Soderling E. Protein composition, adhesion, and agglutination properties of saliva in burning mouth syndrome. Scand J Dent Res 1993 : 101 : 215 258.
21. Lamey PJ, Murray BM, Eddie SA, Freeman RE. The secretion of parotid saliva as stimulated by 10% citric acid is not related to precipitating factors in burning mouth syndrome. J Oral Pathol Med 2001 : 30 : 121 124.
22. Nagler RM, Hershkovich O. Sialochemical and gustatory analysis in patients with oral sensory complaints. J Pain 2004 : 5 : 56 63.
23. Granot M, Nagler RM. Association between regional idiopathic neuropathy and salivary involvement as the possible mechanism for oral sensory complaints. J Pain 2005 : 6 : 581 587.
24. de Moura SA, de Sousa JM, Lima DF, Negreiros AN, Silve Fde V, Costa LJ. Burning mouth syndrome (BMS): sialometric and sialochemical analysis and salivary protein profile. Gerodontology 2007 : 24 : 173 176.
25. Pekiner FN, Gumru B, Demirei GY, Ozbayrak S. Burning mouth syndrome and saliva: detection of salivary trace elements and cytokines. J Oral Pathol Med 2009 : 38 : 269 275.
26. Boras VV, Brailo V, Lukac J, Kordic D, Blazic-Potocki Z. Salivary interleukin-6 and tumor necrosis factor-alpha in patients with burning mouth syndrome. Oral Dis 2006 : 12 : 353 355. (Pubitemid 43736427)
27. Simcic D, Pezelj-Ribaric S, Grzic R, Horvat J, Brumini G, Muhvic-Urek M. Detection of salivary interleukin 2 and interleukin 6 in patients with burning mouth syndrome. Mediators Inflamm 2006 : 2006 : 54632.
28. Suh KI, Kim YK, Kho HS. Salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in patients with burning mouth syndrome. Arch Oral Biol 2009 : 54 : 797 802.
29. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome and other oral sensory disorders: a unifying hypothesis. Pain Res Manag 2003 : 8 : 133 135.
30. Bartoshuk LM, Snyder DJ, Grushka M, Berger AM, Duffy VB, Kveton JF. Taste damage: previously unsuspected consequences. Chem Senses 2005 : 30 (Suppl 1 i218 i219.
31. Eliav E, Kamran B, Schaham R, Czerninski R, Gracely RH, Benoliei R. Evidence of chorda tympani dysfunction in patients with burning mouth syndrome. J Am Dent Assoc 2007 : 138 : 628 633.
32. Formaker BK, Mott AE, Frank ME. The effects of topical anesthesia on oral burning in burning mouth syndrome. Ann N Y Acad Sci 1998 : 855 : 776 780.
33. Just T, Steiner S, Pau HW. Oral pain perception and taste in burning mouth syndrome. J Oral Pathol Med 2010 : 39 : 22 27. Epub 2009 Oct 4.
34. Femiano F. Damage to taste system and oral pain: burning mouth syndrome. Minerva Stomatol 2004 : 53 : 471 478.
35. Wandeur T, de Moura SA, de Medeiros AM, et al. Exfoliative cytology of the oral mucosa in burning mouth syndrome: a cytomorphological and cytomorphometric analysis. Gerodontology 2009 Aug 21. [Epub ahead of print LA, Rogers RS 3rd. Burning mouth syndrome. Dermatol Clin 2003 : 21 : 135 145.
36. Grushka M, Sessle BJ, Miller R. Pain and personality profiles in burning mouth syndrome. Pain 1987 : 28 : 155 167. (Pubitemid 17008034)
37. Browning S, Hislop S, Scully C, Shirlaw P. The association between burning mouth syndrome and psychosocial disorders. Oral Surg Oral Med Oral Pathol 1987 : 64 : 171 174.
38. Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 1999 : 28 : 350 354.
39. Bogetto F, Maina G, Ferro G, Carbone M, Gandolfo S. Psychiatric comorbidity in patients with burning mouth syndrome. Psychosom Med 1998 : 60 : 378 385.
40. Trombelli L, Zangari F, Calura G. [The psychological aspects of patients with the burning mouth syndrome]. Minerva Stomatol 1994 : 43 : 215 221.
41. Cerchiari DP, de Moricz RD, Sanjar FA, Rapoport PB, Moretti G, Guerra MM. Burning mouth syndrome: etiology. Braz J Otorhinolaryngol 2006 : 72 : 419 423.
42. Salort-Llorca C, Minguez-Serra MP, Silvestre FJ. Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Oral Cir Bucal 2008 : 13 : E167 E170.
43. Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980 : 25 : 1 10.
44. Epstein JB, Pearsall NN, Truelove EL. Quantitative relationships between Candida albicans in saliva and the clinical status of human subjects. J Clin Microbiol 1980 : 12 : 475 476.
45. Chen Q, Samaranayake LP. Growth of the fungal pathogen Candida in parotid saliva of patients with burning mouth syndrome. Microbios 2000 : 102 : 45 52.
46. Brooke RI, Seganski DP. Etiology and investigation of the sore mouth. Dent J 1977 : 43 : 504 506.
47. Femiano F. Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Minerva Stomatol 2002 : 51 : 405 409.
48. Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 : 88 : 683 686.
49. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain 2004 : 108 : 51 57.
50. Epstein JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol 1994 : 77 : 135 140.
51. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study. J Oral Pathol Med 2004 : 33 : 111 114.
52. Epstein JB, Truelove EL, Oien H, Le ND, Epstein MS. Oral topical doxepin rinse: anesthetic effect in normal subjects. Pain Res Manag 2003 : 8 : 195 197.
53. Epstein JB, Epstein, JD, Epstein MS, Oien H, Truelove EL. Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy. Spec Care Dentist 2008 : 28 : 73 77.
54. Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: a placebo-controlled, double-blind study. J Orofac Pain 1999 : 13 : 83 88.
55. Heckmann SM, Heckmann JG, Ungethum A, Hujoel P, Hummel T. Gabapentin has little or no effect in the treatment of burning mouth syndrome - results of an open-label pilot study. Eur J Neurol 2006 : 13 : e6 e7.
56. White TL, Kent PF, Kurtz DB, Emko P. Effectiveness of gabapentin for treatment of burning mouth syndrome. Arch Otolaryngol Head Neck Surg 2004 : 130 : 786 768.
57. Lopez V, Alonso V, Marti N, Calduch L, Jorda E. Marked response of burning mouth syndrome to pregabalin treatment. Clin Exp Dermatol 2009 : 34 : e449 e4450.
58. Gorsky M, Silverman Jr. S, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol 1991 : 72 : 192 195.
59. Yamazaki Y, Hata H, Kitamori S, Onodera M, Kitagawa Y. An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 : 107 : e6 e11.
60. Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002 : 63 : 38 43.
61. Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998 : 86 : 557 561.
62. Ueda N, Kodama Y, Hori H, et al. Two cases of burning mouth syndrome treated with olanzapine. Psychiatry Clin Neurosci 2008 : 62 : 359 361.
63. Stuginski-Barbosa J, Rodrigues GG, Bigal ME, Speciali JG. Burning mouth syndrome responsive to pramipexol. J Headache Pain 2008 : 9 : 43 45.
64. Steele JC, Bruce AL, Drage LA, Rogers RS 3rd. Alpha-lipoic acid treatment of 31 patients with sore, burning mouth. Oral Dis 2008 : 14 : 529 532.
65. Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. Eur J Pain 2009 : 13 : 492 496.
66. Cavalcanti DR, da Silveira FR. Alpha lipoic acid in burning mouth syndrome-a randomized double-blind placebo-controlled trial. J Oral Pathol Med 2009 : 38 : 254 261.
67. Lopez-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil 2009 : 36 : 52 57.
68. Bergdahl J, Anneroth G, Perris H. Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: a controlled study. J Oral Pathol Med 1995 : 24 : 213 215.
69. Femiano F, Gombos F, Scully C. Burning Mouth Syndrome: open trial of psychotherapy alone, medication with alpha-lipoic acid (thioctic acid), and combination therapy. Med Oral 2004 : 9 : 8 13.